JP2013538853A5 - - Google Patents

Download PDF

Info

Publication number
JP2013538853A5
JP2013538853A5 JP2013531717A JP2013531717A JP2013538853A5 JP 2013538853 A5 JP2013538853 A5 JP 2013538853A5 JP 2013531717 A JP2013531717 A JP 2013531717A JP 2013531717 A JP2013531717 A JP 2013531717A JP 2013538853 A5 JP2013538853 A5 JP 2013538853A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
topical pharmaceutical
oxymetazoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013531717A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013538853A (ja
Filing date
Publication date
Priority claimed from US13/232,134 external-priority patent/US20120082625A1/en
Application filed filed Critical
Publication of JP2013538853A publication Critical patent/JP2013538853A/ja
Publication of JP2013538853A5 publication Critical patent/JP2013538853A5/ja
Pending legal-status Critical Current

Links

JP2013531717A 2010-09-28 2011-09-27 酒瘡の併用による治療 Pending JP2013538853A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38726010P 2010-09-28 2010-09-28
US61/387,260 2010-09-28
US13/232,134 2011-09-14
US13/232,134 US20120082625A1 (en) 2010-09-28 2011-09-14 Combination treatment for rosacea
PCT/US2011/053440 WO2012047645A2 (en) 2010-09-28 2011-09-27 Combination treatment for rosacea

Publications (2)

Publication Number Publication Date
JP2013538853A JP2013538853A (ja) 2013-10-17
JP2013538853A5 true JP2013538853A5 (enExample) 2014-09-18

Family

ID=45890007

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013531717A Pending JP2013538853A (ja) 2010-09-28 2011-09-27 酒瘡の併用による治療

Country Status (11)

Country Link
US (3) US20120082625A1 (enExample)
EP (1) EP2621497A4 (enExample)
JP (1) JP2013538853A (enExample)
KR (1) KR20140056130A (enExample)
CN (1) CN103354743A (enExample)
AU (1) AU2011312518A1 (enExample)
BR (1) BR112013007343A2 (enExample)
CA (1) CA2811783A1 (enExample)
MX (1) MX2013003638A (enExample)
RU (1) RU2013113184A (enExample)
WO (1) WO2012047645A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
WO2012075319A2 (en) * 2010-12-03 2012-06-07 Allergan, Inc. Pharmaceutical cream compositions and methods of use
ES2742273T3 (es) 2011-02-15 2020-02-13 Aclaris Therapeutics Inc Composiciones de crema farmacéuticas de oximetazolina para tratar los síntomas de la rosácea
CN104666239A (zh) * 2013-11-27 2015-06-03 杭州赛利药物研究所有限公司 酒石酸溴莫尼定凝胶及其制备方法
BR112017017448A2 (pt) * 2015-02-24 2018-04-03 Ocugen Inc métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
US9989950B2 (en) 2015-07-17 2018-06-05 General Electric Company Systems and methods for generating control logic
FR3041537B1 (fr) * 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee contenant de la brimonidine et son utilisation dans le traitement de la rosacee.
EP3434271B1 (en) * 2016-03-22 2020-08-26 Doris Maria Hexsel Use of pharmaceutical composition for the treatment of poikiloderma of civatte
WO2018000067A1 (pt) * 2016-06-28 2018-01-04 Doris Maria Hexsel Uso de uma substância ativa no tratamento do melasma telangiectásico
WO2018065546A1 (en) * 2016-10-07 2018-04-12 Micreos Human Health B.V. Vasoconstricitve and antibacterial combination treatment for rosacea
US10814001B1 (en) 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
RU2766973C1 (ru) * 2021-10-05 2022-03-16 Татьяна Сергеевна Русина Способ сочетанной терапии розацеа эритематозно-телеангэктатического подтипа

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
DK1761266T3 (da) * 2004-05-25 2013-08-05 Galderma Pharma Sa Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme
EP2818184B1 (en) * 2007-11-16 2018-10-31 Allergan, Inc. Compositions and methods for treating Purpura
FR2942138A1 (fr) * 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques

Similar Documents

Publication Publication Date Title
JP2013538853A5 (enExample)
RU2013113184A (ru) Комбинированное лечение розацеа
JP2013542930A5 (enExample)
WO2013170068A3 (en) Nuclear transport modulators and uses thereof
WO2012143576A3 (en) Compounds for preventing, reducing and/or alleviating itchy skin condition(s)
WO2012160180A3 (en) Pharmaceutical composition for administration to nails
CL2014002757A1 (es) Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer.
ME02910B (me) Spojevi tetrahidropirolotiazina
CL2014003081A1 (es) Una composicion farmaceutica topica que comprende, en base al peso total de la composicion, 1,5-5 % en peso de terbinafina, 15-35 % en peso de urea y mas que 25 % en peso de agua; y su uso para el tratamiento topico de una infeccion fungica, preferiblemente onicomicosis.
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
CL2013002504A1 (es) Preparacion farmaceutica solida recubierta que comprende a lo menos un ingrediente activo y porque el recubrimiento tiene un espesor de 0,1 a 100nm, de preferencia de 0,3 a 50 nm y mas preferentemente de 0,5 a 35 nm; y su metodo de preparacion
NZ600333A (en) Use of alpha 2 adrenergic receptor agonists for treating or preventing psoriasis
WO2013174615A3 (en) Personal care composition comprising a colling active and a copolymer comprising acrylamidopropyltrimonium chloride
UA113774C2 (xx) Полімерні наночастинки, що складаються з фінастериду та міноксидилу, спосіб їх виготовлення, водна суспензія, що їх містить, фармацевтична композиція на їх основі та їх застосування
HUE061596T2 (hu) Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
JP2017537936A5 (enExample)
MX2011012143A (es) Composiciones adecuadas para el tratamiento topico o infecciones fungicas de la piel y uñas.
AR065317A1 (es) Uso de quitosanos, derivados de quitosanos y una sal fisiologicamente aceptable del mismo para el tratamiento de enfermedades inflamatorias ungueales
ME02405B (me) Spojevi pirazola као inhibitori sglt1
CO6592109A2 (es) Nueva forma cristalina de un derivado de ciclopropilbenzamida
FR2997299B1 (fr) Association d'extraits de plantes, ingredient actif cosmetique et composition les contenant, et utilisation topique cosmetique
HK1222337A1 (zh) 用於施加药物活性成分或化妆品活性成分的局部组合物和载体
DK2802319T3 (da) Fastdosiskombinationsterapi for parkinsons sygdom
WO2013092457A3 (de) Wirkstoffkombinationen aus einer oder mehreren carbonsäuren, insbesondere hydroxycarbonsäuren, und einer oder mehreren physiologisch unbedenklichen hydroxamsäure sowie kosmetische oder dermatologische zubereitungen, solche wirkstoffkombinationen enthaltend